Skip to Content

Atropine / difenoxin Pregnancy and Breastfeeding Warnings

Atropine / difenoxin is also known as: Motofen

Atropine / difenoxin Pregnancy Warnings

Atropine-difenoxin has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal evidence of teratogenicity however pregnant rats receiving 20 times the maximum human dose had an increase in delivery time as well as a significant increase in the percent of stillbirths. There are no controlled data in human pregnancy. Atropine-difenoxin is only recommended for use during pregnancy when the potential benefit justifies the potential risk to the fetus.

See references

Atropine / difenoxin Breastfeeding Warnings

There are no data on the excretion of atropine-difenoxin into human milk. The effects in the nursing infant are unknown. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Motofen (atropine-difenoxin)." Sebela Pharmaceuticals, Roswell, GA.

References for breastfeeding information

  1. "Product Information. Motofen (atropine-difenoxin)." Sebela Pharmaceuticals, Roswell, GA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.